Autoimmune lymphoproliferative syndrome pathophysiology: Difference between revisions
No edit summary |
|||
| Line 24: | Line 24: | ||
==Microscopic Pathology== | ==Microscopic Pathology== | ||
[[Histopathological]] study findings can be helpful to [[diagnose]] [[Autoimmune lymphoproliferative syndrome]]. The findings are | |||
*Paracortical expansion with infiltration of [[polyclonal]] [[TCR]] α/β+ [[DNT]] [[cells]].<ref name="LiHuang2015">{{cite journal|last1=Li|first1=Pu|last2=Huang|first2=Ping|last3=Yang|first3=Ye|last4=Hao|first4=Mu|last5=Peng|first5=Hongwei|last6=Li|first6=Fei|title=Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS)|journal=Clinical Reviews in Allergy & Immunology|volume=50|issue=1|year=2015|pages=55–63|issn=1080-0549|doi=10.1007/s12016-015-8466-y}}</ref> | |||
*[[DNT]] [[cells]] express TIA-1 and CD57, CD45RO negative | |||
*Follicular [[hyperplasia]] | |||
*Polyclonal [[plasmacytosis]] | |||
*[[Spleen]] has expanded [[T cell]] areas dominated by [[DNT]] [[cells]]. | |||
[[File:Gr3.jpg|center|thumb|Histopathology of spleen in ALPS.<ref name="LimStraus1998">{{cite journal|last1=Lim|first1=Megan S.|last2=Straus|first2=Stephen E.|last3=Dale|first3=Janet K.|last4=Fleisher|first4=Thomas A.|last5=Stetler-Stevenson|first5=Maryalice|last6=Strober|first6=Warren|last7=Sneller|first7=Michael C.|last8=Puck|first8=Jennifer M.|last9=Lenardo|first9=Michael J.|last10=Elenitoba-Johnson|first10=Kojo S.J.|last11=Lin|first11=Albert Y.|last12=Raffeld|first12=Mark|last13=Jaffe|first13=Elaine S.|title=Pathological Findings in Human Autoimmune Lymphoproliferative Syndrome|journal=The American Journal of Pathology|volume=153|issue=5|year=1998|pages=1541–1550|issn=00029440|doi=10.1016/S0002-9440(10)65742-2}}</ref>]][[File:Gr1.jpg|center|thumb|Histopathology of lymph nodes in ALPS.<ref name="LimStraus1998" />]]<br /> | |||
==References== | ==References== | ||
Latest revision as of 04:12, 6 August 2021
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome pathophysiology On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome pathophysiology |
|
FDA on Autoimmune lymphoproliferative syndrome pathophysiology |
|
CDC on Autoimmune lymphoproliferative syndrome pathophysiology |
|
Autoimmune lymphoproliferative syndrome pathophysiology in the news |
|
Blogs on Autoimmune lymphoproliferative syndrome pathophysiology |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
|
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome pathophysiology |
Editor-In-Chief: David Teachey, MD [1] Sharmi Biswas, M.B.B.S
Overview
Autoimmune lymphoproliferative syndrome(ALPS) is the first disease in human beings which are caused by apoptosis defect. Defect in FAS signaling cause benign chronic lymphoproliferation followed by accumulation of TCRαβ(+) CD4(-) CD8(-) double-negative T (DNT) cells. FAS also prevent the mailgnant proliferation of lymphocytes , so ALPS patients are at higher risk of developing lymphoma.There is an identified genetic defect in 2/3 rd of the total cases of ALPS. Germline mutation is the most common type. Somatic mutation, mutations in the proteins of FAS ligand(FASL) and caspase are also responsible in some cases.The pathogenesis of ALPS is still not very clear and research is ongoing.
Pathophysiology
Associated Conditions
- Autoimmune cytopenias: Most common. Can be mild to very severe. Can be intermittent or chronic.[1]
- Autoimmune Hemolytic Anemia
- Autoimmune Neutropenia
- Autoimmune Thrombocytopenia
- Other: Can affect any organ system similar to systemic lupus erythematosis (most rare affecting <5% of patients)
- Nervous: Autoimmune cerebellar ataxia; Guillain-Barre; Transverse myelitis
- GI: Autoimmune esophagitis, gastritis, colitis, hepatitis, pancreatitis
- Derm: Urticaria
- Pulmonary: Bronchiolitis obliterans
- Renal: Autoimmune glomerulonephritis, nephrotic syndrome
- Cancer: Secondary neoplasms affect approximately 10% of patients. True prevalence unknown as <20 reported cases of cancer. Most common EBER+ Non-Hodgkin's and Hodgkin's lymphoma
Microscopic Pathology
Histopathological study findings can be helpful to diagnose Autoimmune lymphoproliferative syndrome. The findings are
- Paracortical expansion with infiltration of polyclonal TCR α/β+ DNT cells.[2]
- DNT cells express TIA-1 and CD57, CD45RO negative
- Follicular hyperplasia
- Polyclonal plasmacytosis
- Spleen has expanded T cell areas dominated by DNT cells.
References
- ↑ Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH; et al. (2005). "Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)". Blood. 105 (6): 2443–8. doi:10.1182/blood-2004-09-3542. PMID 15542578.
- ↑ Li, Pu; Huang, Ping; Yang, Ye; Hao, Mu; Peng, Hongwei; Li, Fei (2015). "Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS)". Clinical Reviews in Allergy & Immunology. 50 (1): 55–63. doi:10.1007/s12016-015-8466-y. ISSN 1080-0549.
- ↑ 3.0 3.1 Lim, Megan S.; Straus, Stephen E.; Dale, Janet K.; Fleisher, Thomas A.; Stetler-Stevenson, Maryalice; Strober, Warren; Sneller, Michael C.; Puck, Jennifer M.; Lenardo, Michael J.; Elenitoba-Johnson, Kojo S.J.; Lin, Albert Y.; Raffeld, Mark; Jaffe, Elaine S. (1998). "Pathological Findings in Human Autoimmune Lymphoproliferative Syndrome". The American Journal of Pathology. 153 (5): 1541–1550. doi:10.1016/S0002-9440(10)65742-2. ISSN 0002-9440.